Apogee Therapeutics

2024 was a pivotal year for Apogee, and we're excited to continue to build on that momentum in 2025. We look forward to continuing to progress our potential best-in-class monotherapy and combination approaches in #atopicdermatitis, #asthma, #eosinophilicesophagitis, #COPD and other I&I indications throughout the year. Learn more about what we’re anticipating for Apogee in 2025 below.

We are excited to announce that we have initiated dosing in a Phase 1 healthy volunteer clinical trial for APG333 - a novel, subcutaneous, half-life extended monoclonal antibody targeting thymic stromal lymphopoietin (#TSLP), which is being initially evaluated as a treatment for people living with #asthma, #COPD and broader I&I conditions. CMO Carl Dambkowski shares more on this milestone in the evolution of our pipeline below. Details here. https://lnkd.in/eTmHFB9h

Apogee is driving transformative change in #immune and #inflammatory diseases by developing treatments that could offer improved efficacy and reduced injection burdens compared to current options. Yesterday, we shared several significant updates from across our pipeline and outlined plans for continued innovation in 2025 and beyond. Click through below for R&D Day highlights, and find more details here. https://lnkd.in/ey4dZfbR

Today, we look forward to highlighting updates from across our pipeline, including positive interim results from the APG808 Phase 1 trial, updated data up to 12 months from the APG777 Phase 1 trial, and details on our combination strategy for #atopicdermatitis, #asthma, #COPD to potentially deliver better efficacy and dosing regimens, during today's virtual R&D Day. Learn more and register to listen live beginning at 10 a.m. ET here. https://lnkd.in/ey4dZfbR

On Monday, December 2nd at 10 am ET, we will be hosting our inaugural R&D Day featuring members of our management team providing updates from across our pipeline and key opinion leaders discussing the current I&I landscape and the need for new treatment options. Check out the full agenda below. https://lnkd.in/etGgG9GS

#COPD is the third leading cause of death worldwide. Today is #WorldCOPDDay - an important reminder of the need for improved treatment options to reduce the burden this long-term disease has on patients and the healthcare system. Learn more about COPD from the American Lung Association. https://lnkd.in/gDT6eJ4m

We are excited to announce we will host a virtual R&D Day on Monday, December 2, 2024 at 10am ET to highlight progress across our pipeline and showcase our path to reshaping the standard of care in I&I by bringing forward monotherapy and combination treatments that offer the potential for best-in-class efficacy and improved dosing.

We are thrilled to share that Apogee has earned a spot on the BioSpace 2025 #BestPlacetoWork list! At Apogee, we put people first. Our C.O.R.E. values of Caring, Original, Resilient and Egoless create an environment where team members thrive and make an impact for patients in need by developing potential new treatment options. Read more in the BioSpace 2025 Best Places to Work list. https://lnkd.in/gKuFq2cG

Today, we reported Q3 2024 financial results and updates from across our pipeline. We continue to execute across our portfolio and advance potentially transformative therapies for patients living with I&I diseases. Read through key updates below and learn more here. https://lnkd.in/e-J6ZUGH

This month, members of our management team will participate in conferences hosted by Guggenheim, Stifel, and Jefferies. Learn more: https://lnkd.in/en9Z83pg